Safian Robert D.
Division of Cardiology, Department of Medicine, William Beaumont Hospital, Heart Center, 3rd Floor, 3601 W. 13 Mile Road, Royal Oak, MI 48073, USA.
Curr Treat Options Cardiovasc Med. 2003 Apr;5(2):91-101. doi: 10.1007/s11936-003-0017-9.
The clinical diagnosis of renal artery stenosis relies on a high index of suspicion and confirmation by noninvasive imaging modalities. There are three distinct clinical syndromes associated with renal artery stenosis: renin-dependent hypertension, essential hypertension, and ischemic nephropathy. Clinical features that should heighten suspicion for renal artery stenosis include abrupt-onset or accelerated hypertension at any age, unexplained acute or chronic azotemia, azotemia induced by angiotensin-converting enzyme (ACE) inhibitors, asymmetric renal dimensions, and congestive heart failure with normal ventricular function. Patients with true renin-dependent (renovascular) hypertension are typically young or middle-age women with renal fibromuscular dysplasia (FMD). Initial therapy for renovascular hypertension associated with FMD is an ACE inhibitor; refractory hypertension responds readily to balloon angioplasty without stenting. Elderly patients with generalized atherosclerosis and hypertension often have atherosclerotic renal artery stenosis (ARAS); hypertension in these patients is usually not renin dependent (ie, essential hypertension). Hypertension alone, even if treated with multiple medications, is not a compelling indication for renal artery revascularization; these patients should be treated aggressively with antihypertensive medical therapy. Renal artery revascularization with stenting may be considered for refractory severe hypertension, and would be expected to improve blood control and modestly reduce medication requirements. Renal revascularization rarely cures hypertension in patients with ARAS. Patients with ARAS, hypertension, and end-organ injury should be considered for renal revascularization. Manifestations of end-organ injury include nonischemic pulmonary edema; hypertensive crisis associated with acute coronary syndrome, aortic dissection, or neurologic impairment; and renal insufficiency. Ischemic nephropathy is best treated before the development of advanced renal failure. The best candidates for revascularization are those with baseline serum creatinine less than 2.0 mg/dL, bilateral renal artery stenosis, normal renal resistive indices, no proteinuria, and one or more manifestations of end-organ injury. In these patients, renal revascularization is best accomplished by stenting, although surgical revascularization may be considered in patients with concomitant severe aortic aneurysmal or occlusive disease.
肾动脉狭窄的临床诊断依赖于高度的怀疑指数以及通过非侵入性成像方式进行的确认。与肾动脉狭窄相关的有三种不同的临床综合征:肾素依赖性高血压、原发性高血压和缺血性肾病。应提高对肾动脉狭窄怀疑的临床特征包括任何年龄的突发或加速性高血压、不明原因的急性或慢性氮质血症、血管紧张素转换酶(ACE)抑制剂诱发的氮质血症、双侧肾脏大小不对称以及心室功能正常的充血性心力衰竭。真正的肾素依赖性(肾血管性)高血压患者通常是患有肾纤维肌发育不良(FMD)的年轻或中年女性。与FMD相关的肾血管性高血压的初始治疗是使用ACE抑制剂;难治性高血压对无支架的球囊血管成形术反应良好。患有全身性动脉粥样硬化和高血压的老年患者常患有动脉粥样硬化性肾动脉狭窄(ARAS);这些患者的高血压通常不是肾素依赖性的(即原发性高血压)。仅高血压,即使使用多种药物治疗,也不是肾动脉血运重建的有力指征;这些患者应积极接受抗高血压药物治疗。对于难治性重度高血压,可考虑进行带支架的肾动脉血运重建,预期可改善血压控制并适度减少药物需求。肾动脉血运重建很少能治愈ARAS患者的高血压。患有ARAS、高血压和终末器官损伤的患者应考虑进行肾动脉血运重建。终末器官损伤的表现包括非缺血性肺水肿;与急性冠状动脉综合征、主动脉夹层或神经功能障碍相关的高血压危象;以及肾功能不全。缺血性肾病最好在晚期肾衰竭发生之前进行治疗。血运重建的最佳候选者是那些基线血清肌酐低于2.0mg/dL、双侧肾动脉狭窄、肾阻力指数正常、无蛋白尿且有一项或多项终末器官损伤表现的患者。在这些患者中,肾动脉血运重建最好通过支架置入来完成,尽管对于伴有严重主动脉瘤或闭塞性疾病的患者可考虑进行外科血运重建。